Semaglutide sublingual - iX Biopharma
Alternative Names: iXB-401; Sublingual semaglutide wafer - iX BiopharmaLatest Information Update: 11 Feb 2025
At a glance
- Originator iX Biopharma
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus; Obesity
Most Recent Events
- 20 Jan 2025 Preclinical trials in Diabetes mellitus in Singapore (Sublingual) (iX Biopharma pipeline; January 2025)
- 20 Jan 2025 Preclinical trials in Obesity in Singapore (Sublingual) (iX Biopharma pipeline; January 2025)
- 12 Nov 2024 Pharmacokinetics data from preclinical trial in Obesity and Diabetes mellitus released by iX Biopharma